Skip to main content

Cavu Management, LP's Form 4 filing

Lantern Pharma Inc. (LTRN) · filed May 28, 2024

Accession no.
0001104659-24-065619
Filed
May 28, 2024, 4:31 PM ET
Trade date
May 23-24, 2024
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market sales total $189.1K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cavu Management, LPCIK 000181327010% Owner
Cavu Advisors, LLCCIK 000181331010% Owner
BP Directors, LPCIK 000181331110% Owner
Kreis Leslie W.CIK 000181331610% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 23, 2024Common StockSSaleDisposed−930$6.25−$5,812.559,326IndirectDuplicate filing
May 24, 2024Common StockSSaleDisposed−1,859$6.33−$11,767.4757,467IndirectDuplicate filing
May 23, 2024Common StockSSaleDisposed−6,944$6.25−$43,400443,174IndirectDuplicate filing
May 24, 2024Common StockSSaleDisposed−13,888$6.33−$87,911.04429,286IndirectDuplicate filing
May 23, 2024Common StockSSaleDisposed−2,126$6.25−$13,287.5135,706IndirectDuplicate filing
May 24, 2024Common StockSSaleDisposed−4,253$6.33−$26,921.49131,453IndirectDuplicate filing

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)